P3 Health Partners Inc. $PIII Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC cut its holdings in shares of P3 Health Partners Inc. (NASDAQ:PIII) by 98.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,369 shares of the company’s stock after selling 1,834,892 shares during the quarter. Corient Private Wealth LLC owned about 0.49% of P3 Health Partners worth $223,000 at the end of the most recent reporting period.

Separately, Trinity Financial Advisors LLC lifted its stake in P3 Health Partners by 22.5% in the 1st quarter. Trinity Financial Advisors LLC now owns 1,278,037 shares of the company’s stock worth $222,000 after purchasing an additional 234,500 shares in the last quarter. Institutional investors own 7.75% of the company’s stock.

P3 Health Partners Stock Down 1.4%

PIII stock opened at $3.49 on Friday. P3 Health Partners Inc. has a one year low of $3.40 and a one year high of $14.50. The firm has a market cap of $25.16 million, a PE ratio of -0.09 and a beta of 0.90. The firm’s 50 day moving average price is $5.92 and its 200-day moving average price is $7.03. The company has a debt-to-equity ratio of 2.29, a quick ratio of 0.32 and a current ratio of 0.32.

P3 Health Partners (NASDAQ:PIII) last posted its earnings results on Thursday, November 13th. The company reported ($9.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.70) by ($0.97). P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 9.07%.The business had revenue of $345.25 million for the quarter, compared to analyst estimates of $346.64 million. On average, equities research analysts anticipate that P3 Health Partners Inc. will post -0.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Lake Street Capital dropped their price target on P3 Health Partners from $20.00 to $12.50 and set a “buy” rating for the company in a research report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of P3 Health Partners in a report on Wednesday, October 8th. Finally, BTIG Research reiterated a “neutral” rating on shares of P3 Health Partners in a report on Friday, December 12th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $12.50.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.